کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3327389 1212177 2014 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Path-breaking target therapies for lung cancer and a far-sighted health policy to support clinical and cost effectiveness
ترجمه فارسی عنوان
درمان های هدفمند برای درمان سرطان ریه و یک سیاست سلامت دور چشم برای حمایت از اثربخشی بالینی و هزینه
کلمات کلیدی
سرطان ریه، هدف درمان زیست شناسی مولکولی، نوآوری رادیکال، داروهای با هزینه بالا سیاست سلامت
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی انفورماتیک سلامت
چکیده انگلیسی


• Targeted therapies for lung cancer are generating a revolution in clinical practice.
• Target therapies for lung cancer can improve the overall survival and quality of life in patients.
• Ground-breaking target therapies for advanced non-small cell lung cancer may replace standard chemotherapy approaches.
• Target therapies for lung cancer should be applied as first-line treatments to have more clinical and cost effectiveness.
• High-cost of path-breaking anticancer drugs (target therapies) has frictional effects on their adoption in healthcare.

The purpose of this paper is to analyze the radical innovations to treat lung cancer, which are generating a revolution in clinical practice, in order to provide fruitful health policy implications. The finding shows an allometric process of scientific growth of target therapies: disproportionate knowledge growth of the new anticancer drug (Gefitinib) in relation to the standard platinum-based chemotherapy. These ground-breaking target therapies for advanced non-small cell lung cancer (NSCLC) may replace standard chemotherapy approaches, which might enter into a maturity phase in the not-too-distant future. The current debate concerns some uncertainties about the efficacy, the long-term effects of these radical innovations on carcinogenesis and the high cost of these new anticancer drugs for healthcare system. Nevertheless, these innovative treatments generate several benefits in terms of higher survival and quality of life. The development of path-breaking target therapies for NSCLC and the efficiency of personalized healthcare system should be based on the understanding of cancer biology, E-health system and chemoprevention (e.g. early stage biomarkers) to improve stratification of patients and the precision of first-line target therapies: this strategy may increase the fruitful effects of new multi-inhibitors blocking agents and their cost effectiveness; in addition, it is also important a long-run systemic evaluation of costs, based on clinical and economic monitoring of patients to support a far-sighted health policy.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Health Policy and Technology - Volume 3, Issue 1, March 2014, Pages 74–82
نویسندگان
,